Bipartisan congressional lawmakers say they’re working to codify into law an executive order President Donald Trump issued to streamline research and access into psychedelic medicine.
Reps. Lou Correa (D-CA) and Jack Bergman (R-MI)—co-chairs of the Congressional Psychedelics Advancing Therapies (PATH) Caucus—both recently spoke about the need to enact into law provisions to protect the intent of the executive action to ensure ongoing support for psychedelics research for military veterans and people with certain mental health conditions even under future president’s.
During an interview with CBS News last week, Correa was asked about potential complications with the president’s action given that Marty Makary resigned as head of the Food and Drug Administration (FDA), which plays a key role in advancing drug research and development.
He are Bergman are “working jointly to make sure we put this into legislation—to move forward permanently, finding a solution for PTSD, every day in America,” Correa said, adding that he the novel therapy “will revolutionize the way we treat mental health in America” and potentially “lead to helping us with” addressing homelessness.
President Trump signed an executive order last month that speeds up research and increases federal funding for psychedelic drug therapies. Rep. Lou
Read full article on Marijuana Moment
